Alcon Inc. (ETR:2U3)
Germany · Delayed Price · Currency is EUR | Market Cap | 30.31B -6.1% |
| Revenue (ttm) | 9.51B +8.3% |
| Net Income | 562.82M -40.1% |
| EPS | 1.15 -39.2% |
| Shares Out | n/a |
| PE Ratio | 54.60 |
| Forward PE | 17.35 |
| Dividend | 0.31 (0.49%) |
| Ex-Dividend Date | May 5, 2026 |
| Volume | 1,993 |
| Open | 60.36 |
| Previous Close | 60.36 |
| Day's Range | 60.36 - 62.84 |
| 52-Week Range | 52.42 - 74.62 |
| Beta | 0.73 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 11, 2026 |
About Alcon
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS... [Read more]
Financial Performance
In 2025, Alcon's revenue was $10.40 billion, an increase of 4.94% compared to the previous year's $9.91 billion. Earnings were $980.00 million, a decrease of -3.73%.
Financial numbers in USD Financial StatementsNews
Alcon (ALC) Completes $550M Acquisition of Neurotech Pharmaceuticals
Alcon (ALC) Completes $550M Acquisition of Neurotech Pharmaceuticals
Alcon (ALC) Expands Eye Care Portfolio with Neurotech Pharmaceuticals Acquisition
Alcon (ALC) Expands Eye Care Portfolio with Neurotech Pharmaceuticals Acquisition
Alcon acquires Neurotech and expands retina portfolio with ENCELTO
Alcon (ALC) announced it has acquired Neurotech Pharmaceuticals, a company focused on developing innovative cell therapies for chronic and neurodegenerative eye diseases. This acquisition expands Alco...
Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2
GENEVA--(BUSINESS WIRE)--Alcon Acquires Neurotech and ENCELTO, the Only FDA Approved Treatment for MacTel Type 2.
Alcon Secures FDA Approval For BRYTLY OTC Redness Relief Eye Drops
(RTTNews) - Alcon (ALC, ALC.SW) announced that the U.S. Food and Drug Administration approved BRYTLY Redness Reliever Eye Drops, an over-the-counter treatment designed to reduce eye redness.
Alcon's Brytly Approved for OTC Sale, Boosting Growth Prospects for ALC
Alcon's Brytly Approved for OTC Sale, Boosting Growth Prospects for ALC
Alcon (ALC) Gains FDA Approval for Brytly Redness Reliever Eye Drops
Alcon (ALC) Gains FDA Approval for Brytly Redness Reliever Eye Drops
Alcon announces FDA approval of Brytly Redness Reliever Eye Drops
Alcon (ALC) announced that the U.S. FDA has approved Brytly Redness Reliever Eye Drops. With one drop, Brytly works in just one minute to significantly reduce redness and delivers up…
FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
GENEVA--(BUSINESS WIRE)--FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes.
FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
One drop works to significantly reduce redness, with results lasting up to 12 hours1 Lasts up to 50% longer than Lumify1-2,* Expands Alcon's portfolio of consumer eye care solutions and will be av...
FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
GENEVA--(BUSINESS WIRE)--FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes.
A Look at Alcon Inc (ALC) After 4.2% Gain -- GF Value $87.46 vs Price $66.58
A Look at Alcon Inc (ALC) After 4.2% Gain -- GF Value $87.46 vs Price $66.58
Alcon price target lowered to $80 from $85 at Mizuho
Mizuho lowered the firm’s price target on Alcon (ALC) to $80 from $85 and keeps an Outperform rating on the shares. The firm adjusted targets in the medical devices and…
Alcon price target lowered to $74 from $82 at BTIG
BTIG lowered the firm’s price target on Alcon (ALC) to $74 from $82 and keeps a Buy rating on the shares as part of a broader research note previewing Q3…
Alcon initiated with an Equal Weight at Barclays
Barclays analyst Christopher Pasquale initiated coverage of Alcon (ALC) with an Equal Weight rating and $70 price target The firm rolled out coverage of the medical suppliers and devices group…
Introducing Systane PRO PRESERVATIVE-FREE: Alcon’s Longest Lasting, Triple-Action Formula for up to 12 Hours of Dry Eye Symptom Relief
Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced the launch of Systane PRO Preservative-Free (PF) in Canada as Systane’s most advanced formula. Systane...
Alcon Becomes Oversold (ALC)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Alcon price target lowered to $85 from $95 at Jefferies
Jefferies analyst Michael Sarcone lowered the firm’s price target on Alcon (ALC) to $85 from $95 and keeps a Buy rating on the shares. The ophthalmology sector has been under…
Alcon announces initial commercial launch of UNITY M
Alcon (ALC) announced the initial commercial launch of UNITY M, an Alcon brand premium surgical microscope that delivers precise control to ophthalmic surgeons, in select markets including the U.S. an...
Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control
GENEVA--(BUSINESS WIRE)--Alcon Launches UNITY® M, a Premium Ophthalmic Microscope Delivering Precise Control.
Platauro Metals Corp. - Star Project, Utah
Vancouver, British Columbia--(Newsfile Corp. - September 2, 2026) - Platauro Metals Corp. (TSXV: PURO) (OTCQB: MEXGF) ("Platauro" or the "Company") announces that its wholly-owned subsidiary, Alcon Si...
Alcon Prices EUR 500 Million Senior Notes Offering
GENEVA--(BUSINESS WIRE)--Alcon Prices EUR 500 Million Senior Notes Offering.
Alcon’s Q2 2026 Growth Shows UNITY Momentum, but Cataract Softness and Implantables Competition Still Matter
What the latest reported quarter says about the current operating story and the main business drivers Alcon Inc. (NYSE: ALC)... The post Alcon’s Q2 2026 Growth Shows UNITY Momentum, but Cataract Softn...
Alcon (ALC) Q2 2026 Earnings Call Transcript
Net sales grew 7% to $2.8 billion as surgical and vision care divisions both expanded.
Alcon price target raised to CHF 73 from CHF 70 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Alcon (ALC) to CHF 73 from CHF 70 and keeps a Buy rating on the shares.